Analyst predicts blockbuster potential for Biomarin's growth hormone

The US-based biotech company Biomarin is edging closer to the launch of dwarfism drug Voxzogo and one analyst sees signs of a potential blockbuster. The US Food and Drug Administration is expected to reach a decision this week.

Photo: Anders Rye Skjoldjensen

Within the week, Biomarin will know whether it has received the green light to market Voxzogo – its treatment for achondroplasia, also known as dwarfism – from the US Food and Drug Administration (FDA).

The growth hormone has already been approved across the Atlantic, and Senior Research Analyst at SVB Leerink Joseph P. Schwartz has assessed that the drug has the potential to breathe new life into Biomarin's stagnating growth, as reported by industry media Fierce Pharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs